Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 7,600 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 7,600 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $85.38, for a total transaction of $648,888.00. Following the completion of the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at $5,225,426.76. This represents a 11.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $85.40 on Friday. The firm has a market capitalization of $6.97 billion, a price-to-earnings ratio of -23.21 and a beta of 2.28. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The company has a 50-day moving average of $81.26 and a 200 day moving average of $71.73.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.Kymera Therapeutics’s revenue was down 60.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.88) earnings per share. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. boosted its position in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. boosted its position in Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares in the last quarter.

Analysts Set New Price Targets

KYMR has been the topic of several research reports. Bank of America raised their price objective on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Wells Fargo & Company raised their price target on Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Truist Financial lifted their price objective on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Piper Sandler upped their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.